{"id":25649,"date":"2023-11-16T18:00:00","date_gmt":"2023-11-16T12:30:00","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25649"},"modified":"2024-09-27T18:05:12","modified_gmt":"2024-09-27T12:35:12","slug":"medtech-news-for-samsung-lunit-vivasure-ge","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge","title":{"rendered":"GE Healthcare and Masimo Announced Collaboration; Samsung Launched New Ultrasound System \u2018V6\u2019; MONARCH Platform Approved for Bronchoscopy in China; Lunit Received FDA Nod for Lunit INSIGHT DBT; Route 92 Medical Releases Tenzing Technology Clinical Findings; Vivasure Medical Enrolled 100th Patient for its Vivasure PerQseal Closure Device System Study"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69e738bba0701\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69e738bba0701\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge\/#GE_HealthCare_and_Masimo_Collaborated_on_Patient_Monitoring_Tech\" >GE HealthCare and Masimo Collaborated on Patient Monitoring Tech<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge\/#Samsung_Launched_New_Ultrasound_System_%E2%80%98V6_with_Comprehensive_Imaging_Capabilities\" >Samsung Launched New Ultrasound System \u2018V6\u2019 with Comprehensive Imaging Capabilities<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge\/#MONARCH_Platform_for_Bronchoscopy_Received_Regulatory_License_for_China\" >MONARCH Platform for Bronchoscopy Received Regulatory License for China<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge\/#Lunit_Received_FDA_Nod_for_AI-Powered_3D_Breast_Tomosynthesis_Solution_Lunit_INSIGHT_DBT\" >Lunit Received FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge\/#Route_92_Medical_Announced_Clinical_Results_for_its_Tenzing%C2%AE_Technology\" >Route 92 Medical Announced Clinical Results for its Tenzing\u00ae Technology<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge\/#Vivasure_Medical_Announced_100th_Patient_Enrolled_in_the_US_Pivotal_Study_of_its_Vivasure_PerQseal%C2%AE_Closure_Device_System\" >Vivasure Medical Announced 100th Patient Enrolled in the US Pivotal Study of its Vivasure PerQseal\u00ae Closure Device System<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-ge-healthcare-and-masimo-collaborated-on-patient-monitoring-tech\"><span class=\"ez-toc-section\" id=\"GE_HealthCare_and_Masimo_Collaborated_on_Patient_Monitoring_Tech\"><\/span><strong>GE HealthCare and Masimo Collaborated on Patient Monitoring Tech<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> November 8, 2023, GE HealthCare <\/strong>and <strong>Masimo <\/strong>announced a joint agreement to integrate patient monitoring technologies.&nbsp;<\/p>\n\n\n\n<p>The goal of the partnership is to incorporate <strong>Masimo Signal Extraction Technology (SET) pulse oximetry<\/strong> into <strong>GE HealthCare&#8217;s wearable<\/strong>, wireless patient monitoring system, Portrait Mobile.<\/p>\n\n\n\n<p>Cloud-native technology powers Portrait Mobile, an Internet of Medical Things (IoMT) platform. It offers a complete wearable, continuous monitoring experience. In August of this year, Portrait Mobile received FDA approval.<\/p>\n\n\n\n<p>Clinicians can take advantage of Masimo&#8217;s low-perfusion oxygen saturation measurement and measure-through motion capabilities by integrating Masimo SET. It makes non-invasive detection and ongoing patient status monitoring possible.<\/p>\n\n\n\n<p>SET technology is used to monitor post-operative patients on opioids and to lessen blindness in neonatal intensive care unit patients. Additionally, it provided COVID-19 <a href=\"https:\/\/www.delveinsight.com\/report-store\/telehealth-market\"><strong>remote patient monitoring facilities<\/strong><\/a>. Additionally, Masimo&#8217;s ongoing patent dispute with Apple regarding smartwatches revolves around this technology.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cPortrait Mobile is built as an open platform, with the capability to be compatible with other technologies. The ability to integrate Masimo\u2019s innovative SET pulse oximetry in a wearable sensor demonstrates the flexibility and scalability of our new platform while leveraging Masimo\u2019s measurement expertise,\u201d <\/em><strong>said Neal Sandy, GM of Monitoring Solutions at GE HealthCare<\/strong>. Neal added, <em>\u201cClinicians and patients will see the real benefit as Portrait Mobile enhances clinical decision-making for mobile patients and ultimately, supports earlier detection of deterioration.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>As per <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/patient-monitoring-devices-market\"><strong>Patient Monitoring Devices Market<\/strong><\/a><strong>\u201d report<\/strong>, the global patient monitoring devices market was valued at <strong>USD 35.21 billion<\/strong> in 2022, growing at a CAGR of <strong>8.20%<\/strong> during the forecast period from 2023 to 2028, to reach <strong>USD 56.46 billion<\/strong> by 2028. The escalating demand for patient monitoring devices is primarily attributed to the increase in the prevalence of various chronic and lifestyle-associated disorders. Moreover, the sudden outbreak of the COVID-19 pandemic has also contributed to the patient monitoring devices market. Additionally, the growing preferences for remote patient monitoring systems among patients and healthcare providers, the increase in technological advancement in the product arena, and the rise in the approval of various patient monitoring devices in the current year, among others are also some of the factors responsible for potentially increasing the global patient monitoring devices market during the forecast period (2023-2028).<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-samsung-launched-new-ultrasound-system-v6-with-comprehensive-imaging-capabilities\"><span class=\"ez-toc-section\" id=\"Samsung_Launched_New_Ultrasound_System_%E2%80%98V6_with_Comprehensive_Imaging_Capabilities\"><\/span><strong>Samsung Launched New Ultrasound System \u2018V6\u2019 with Comprehensive Imaging Capabilities<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> November 13, 2023<\/strong>, the latest ultrasound system from <strong>Samsung<\/strong>, called the <strong>V6 <\/strong>was launched, designed specifically for women&#8217;s health and urology and offers comprehensive imaging capabilities in 2D, 3D, and color image quality. <strong>Boston Imaging<\/strong>, the company&#8217;s US headquarters for digital radiography and ultrasound business, announced that the U.S. Food and Drug Administration recently granted the V6 510(k) clearance for commercial use. Its cost-effective design satisfies workflow and productivity requirements.<\/p>\n\n\n\n<p>The V6 not only improves image clarity and accuracy but also adapts to different medical settings thanks to its widescreen, compact, powerful design, and battery-operated design. These features increase accessibility and versatility for healthcare providers.<\/p>\n\n\n\n<p>Samsung&#8217;s core imaging platform, Crystal Architecture, powers the V6 ultrasound system, providing improved image clarity and sophisticated automated tools like these:<\/p>\n\n\n\n<p>With a 180\u00b0 field of view for wide-angle imaging and a frequency range of 2-12 MHz to meet a range of imaging requirements, the miniER7 Endocavity Transducer is small enough to ensure patient comfort. Utilizing the probe with a 63% reduced head volume not only resulted in a significant 43% decrease in patient discomfort during prostate ultrasounds without compromising the quality of the images but it is also anticipated to potentially minimize pain during pelvic examinations in women going through menopause.<\/p>\n\n\n\n<p>ViewAssist\u2122 is an <strong><a href=\"https:\/\/www.delveinsight.com\/blog\/top-artificial-intelligence-based-healthcare-mobile-apps\" class=\"ek-link\">artificial intelligence (AI) tool<\/a><\/strong> that helps medical professionals document exams more easily and efficiently by automatically identifying imaging planes and labeling anatomy.<\/p>\n\n\n\n<p>With <strong>BiometryAssist\u2122<\/strong>, a semi-automated feature based on Deep Learning, doctors can concentrate more on patient care by having one-click fetal growth measurements that provide exam consistency while minimizing keystrokes.<\/p>\n\n\n\n<p><strong>UterineAssist\u2122<\/strong> is an artificial intelligence tool that measures the uterus&#8217;s size and shape automatically, aiding in the detection of abnormalities related to the uterus.<\/p>\n\n\n\n<p><strong>Mobile Export: <\/strong>A safe way to share images with friends and family that transfers fetal pictures straight from the ultrasound machine to the patient&#8217;s smartphone via a straightforward <a href=\"https:\/\/www.adobe.com\/express\/feature\/image\/qr-code-generator\" class=\"ek-link\"><strong>QR code<\/strong><\/a>.<\/p>\n\n\n\n<p><strong>SonoSync\u2122: <\/strong>A real-time image-sharing solution that enables doctors and sonographers to communicate for training and care guidelines. Furthermore, real-time marking capabilities, text chat, and voice chat are offered for enhanced communication.<\/p>\n\n\n\n<p>The V6 satisfies applicable FDA guidelines and medical device safety standards and has been assessed for acoustic output, biocompatibility, software functionality, cleaning and disinfection efficacy, and thermal, electrical, electromagnetic, and mechanical safety. It also includes a wide range of transducers suitable for various clinical applications. The V6 is a great fit in the reproductive endocrinology and infertility setting because it works with Cycle Clarity&#8217;s AI-based software platform.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe are thrilled to introduce our latest innovation in Women&#8217;s Health and Urology imaging, reflecting our unwavering commitment to delivering efficient care and meeting the imaging demands of medical professionals,\u201d <\/em><strong>said David Legg, Head of Boston Imaging<\/strong>.<em> \u201cThe V6 provides advanced healthcare technology to clinicians, enabling them to provide a high standard of care.\u201d&nbsp;<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cThe V6 was developed with the clinical needs of Women\u2019s Health and Urology specifically in mind,\u201d <\/em><strong>said Tracy Bury, Women\u2019s Health Segment Leader for Boston Imaging.<\/strong> Tracy commented, <em>\u201cWe\u2019re proud to offer a new product that is not only accessible to a broad group of clinicians but also has innovative, automated features that can make patient care simpler and more efficient.\u201d&nbsp;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/gyneco-obstetric-ultrasound-systems-market\"><strong>Gyneco-Obstetric Ultrasound Systems<\/strong> <strong>Market<\/strong><\/a><strong>\u201d report<\/strong>, the global gyneco-obstetric ultrasound systems market was valued at <strong>USD 2.83 billion<\/strong> in 2022, growing at a CAGR of <strong>5.70%<\/strong> during the forecast period from 2023 to 2028, to reach <strong>USD 3.95 billion<\/strong> by 2028. The demand for gyneco-obstetric ultrasound systems is primarily being boosted by the growing demand for routine pregnancy sonographic scans for detecting complications, increasing prevalence of women&#8217;s gynecological-related diseases such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/polycystic-ovarian-syndrome-market\"><strong>ovarian cysts<\/strong><\/a>; <a href=\"https:\/\/www.delveinsight.com\/report-store\/pelvic-inflammatory-disease-market\"><strong>pelvic pain<\/strong><\/a>; genital infections; infertility, innovation in product development such as 3D and 4D systems, rising adoption due to no radiation exposure, are all contributing to the growth of the Gyneco-obstetric Ultrasound Systems market in the upcoming years.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-monarch-platform-for-bronchoscopy-received-regulatory-license-for-china\"><span class=\"ez-toc-section\" id=\"MONARCH_Platform_for_Bronchoscopy_Received_Regulatory_License_for_China\"><\/span><strong>MONARCH Platform for Bronchoscopy Received Regulatory License for China<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> November 13, 2023<\/strong>, <strong>Johnson &amp; Johnson MedTech<\/strong> announced that the <strong>MONARCH Platform<\/strong> and <strong>MONARCH Bronchoscope<\/strong> received regulatory approval in <strong>China<\/strong>.<\/p>\n\n\n\n<p>The platform is the first J&amp;J MedTech robotically assisted device authorized in China, as well as the first minimally invasive robotic device authorized for peripheral lung procedures. Additionally, this is the first time the MONARCH Platform has received regulatory approval outside of the US.<\/p>\n\n\n\n<p>The MONARCH Platform is designed to facilitate diagnostic and therapeutic procedures by providing bronchoscopic visualization and access to adult patient airways when used in conjunction with the MONARCH Bronchoscope. The gadget makes it possible for medical professionals to perform peripheral lung procedures with robotic assistance and minimal invasiveness.<\/p>\n\n\n\n<p>Since lung cancer nodules are often small, deep in the lungs, and difficult to reach, making early-stage diagnosis and treatment challenging, the ability to reach these hard-to-reach peripheral lung nodules earlier and more precisely is helping to change the future of interventional care for patients. Globally, lung cancer is the primary cause of cancer-related deaths. Research indicates that early detection can boost survival rates by identifying the disease at an earlier stage when treatment outcomes are more likely.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;There are more than two million patients diagnosed with lung cancer each year around the world, and nearly 40% of them are in China,&#8221; <\/em>said <strong>Will Song, President, of Johnson &amp; Johnson MedTech China<\/strong>. Will further added, <em>&#8220;With this approval, MONARCH is poised to aid physicians in China as they work with patients to fight one of the most prevalent and deadly diseases in the country.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;The MONARCH team is committed to driving meaningful innovation that changes the way patients experience healthcare,&#8221;<\/em><strong><em> <\/em>said Adrian Whitford, President, of MONARCH.<\/strong><em> <\/em>Adrian added,<em> &#8220;Expanding the reach of flexible robotic-assisted devices for lung procedures to countries around the world is part of our vision to deliver breakthrough technology that improves clinical outcomes for patients fighting diseases like lung cancer.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to DelveInsight\u2019s <strong>\u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/bronchoscope-market\"><strong>Bronchoscopes<\/strong> <strong>Global Market<\/strong><\/a><strong>\u201d report<\/strong>, the global bronchoscopes market was valued at <strong>USD 19.14 billion<\/strong> in 2022, growing at a CAGR of <strong>7.46%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 29.38 billion<\/strong> by 2028. The bronchoscopes market is witnessing positive market growth owing to factors such as the rising prevalence of various respiratory diseases such as <a href=\"https:\/\/www.delveinsight.com\/report-store\/tuberculosis-market\"><strong>tuberculosis<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-small-cell-lung-cancer-nsclc-market\"><strong>growing prevalence of lung cancers<\/strong><\/a>, <a href=\"https:\/\/www.delveinsight.com\/report-store\/chronic-obstructive-pulmonary-disease-copd-market\"><strong>increasing cases of chronic obstructive pulmonary diseases<\/strong><\/a>, and increasing product development activities concerning bronchoscopes among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-lunit-received-fda-nod-for-ai-powered-3d-breast-tomosynthesis-solution-lunit-insight-dbt\"><span class=\"ez-toc-section\" id=\"Lunit_Received_FDA_Nod_for_AI-Powered_3D_Breast_Tomosynthesis_Solution_Lunit_INSIGHT_DBT\"><\/span><strong>Lunit Received FDA Nod for AI-Powered 3D Breast Tomosynthesis Solution, Lunit INSIGHT DBT<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>November 14, 2023,<\/strong> <strong>Lunit<\/strong>, a leading provider of <strong>AI-powered solutions<\/strong> for cancer diagnostics and therapeutics, announced that it received the <strong>U.S. Food and Drug Administration (FDA) 510(k)<\/strong> clearance for its <strong>3D Breast Tomosynthesis (DBT) AI solution<\/strong>, Lunit INSIGHT DBT.<\/p>\n\n\n\n<p>With this approval, Lunit can now fully enter the US breast screening market, marking a significant advancement in the fight against breast cancer.<\/p>\n\n\n\n<p>Singular Insight DBT is an artificial intelligence algorithm designed to evaluate 3D images produced by DBT apparatus. Using DBT imaging instead of standard 2D mammography screenings allows for a quicker and more precise diagnosis of breast cancer.<\/p>\n\n\n\n<p>Due to DBT&#8217;s ability to perform more accurate breast cancer exams, there is a high demand for this technology worldwide, with over 64% of the demand coming from advanced medical institutions in the US. 88% of the 8,850 facilities in the US that have been accredited by the Mammography Quality Standards Act and Programme (MQSA) as of November 2023 are DBT-certified units.<\/p>\n\n\n\n<p>This FDA approval builds on Lunit&#8217;s November 2021 accomplishments, when the FDA approved its AI-powered mammography analysis tool, &#8220;Lunit INSIGHT MMG,&#8221; and its chest X-ray triage solution, &#8220;Lunit INSIGHT CXR Triage.&#8221;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;The US is the biggest player in the global breast screening market, accounting for up to 40% of the market share. More than 40 million mammography screenings are reported in the US annually,&#8221; <\/em><strong>said Brandon Suh, CEO of Lunit<\/strong>. Brandon mentioned,<em> &#8220;Given this substantial market influence, achieving FDA clearance for Lunit INSIGHT DBT not only solidifies our presence in the largest market but also marks a significant milestone in our mission to revolutionize breast cancer diagnosis and, ultimately, save more lives.&#8221;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/breast-cancer-diagnostics-market\"><strong>Breast Cancer Diagnostics Market<\/strong><\/a><strong>\u201d report,<\/strong> the global breast cancer diagnostics market was valued at <strong>USD 4.20 billion<\/strong> in 2022, growing at a CAGR of <strong>6.67%<\/strong> during the forecast period from 2023 to 2028 to reach <strong>USD 6.16 billion<\/strong> by 2028. The breast cancer diagnostics market is witnessing positive growth owing to factors such as the <a href=\"https:\/\/www.delveinsight.com\/report-store\/breast-cancer-market\"><strong>increasing prevalence of breast cancer<\/strong><\/a>, increasing age and sedentary lifestyle, technological advancements, and government initiatives to increase the rate of screening and diagnosis, all factors contributing to the growth of Breast cancer diagnostics market during the forecast period from 2023-2028.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-route-92-medical-announced-clinical-results-for-its-tenzing-technology\"><span class=\"ez-toc-section\" id=\"Route_92_Medical_Announced_Clinical_Results_for_its_Tenzing%C2%AE_Technology\"><\/span><strong>Route 92 Medical Announced Clinical Results for its Tenzing\u00ae Technology<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On<strong> November 14, 2023, Route 92 Medical<\/strong>, the privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, announced compelling results from a multicenter clinical study1 on the <strong>Tenzing\u00ae 7 Delivery Catheter published in <em>Stroke: Vascular and Interventional Neurology<\/em><\/strong>.<\/p>\n\n\n\n<p>The study, which involved several institutions, sought to assess the Tenzing 7 Delivery Catheter&#8217;s effectiveness, safety, and efficiency in delivering therapeutic devices for mechanical thrombectomy in cases of acute ischemic stroke.<\/p>\n\n\n\n<p><strong>The key findings of the study include:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A 95.9% success rate in deploying Tenzing 7 delivery catheter-powered large-bore reperfusion catheters to the clot face without the requirement for stent retrievers to be anchored.<\/li>\n\n\n\n<li>In 94.9% of cases, recanalization was successful.<\/li>\n\n\n\n<li>In 54.2% of cases, first-pass reperfusion using an aspiration catheter sized 07 was successful. This compares well with the best stent retriever data, even when balloon guides are used, which can be quite laborious.<\/li>\n\n\n\n<li>At hospital discharge, the median NIHSS improvement for the patients was a significant 10 points.<\/li>\n\n\n\n<li>Among the patients, 41.0% had a good functional outcome after 90 days.<\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;Early clinical and in vitro experiences have always shown the potential of the Tenzing 7 delivery catheter. These multicenter results support its position as a game-changer in the field of neurointervention,&#8221; <\/em><strong>said Dan Tonetti, MD, Director, of Acute Stroke and Neurointerventional Suite at Cooper University Health Care, and one of the lead contributors to the study<\/strong>.<\/p>\n<\/blockquote>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>&#8220;These findings underline our unwavering commitment to elevating patient outcomes through the development of best-in-class neurovascular intervention tools,\u201d <\/em><strong>said Joey D. English, MD, PhD, Chief Medical Officer at Route 92 Medical<\/strong>. Joey added further, <em>\u201cThe results illustrate the power of the Tenzing technology to elevate the clinician experience, improve patient outcomes, and set a new benchmark of thrombectomy for the industry as part of a complete stroke treatment solution, such as our recently launched FreeClimb 70 reperfusion system powered by Tenzing 7. Large-bore aspiration catheters reaching the target consistently, without crossing the embolus, have the potential to create fewer downstream effects. Tenzing is a major advance.\u201d&nbsp;<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to <strong>DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neurovascular-devices-interventional-neurology-market\"><strong>Neurovascular Devices Market<\/strong><\/a><strong>\u201d report, <\/strong>the global neurovascular devices market was valued at <strong>USD 2.84 billion<\/strong> in 2022, growing at a CAGR of <strong>8.12%<\/strong> during the forecast period from 2023 to 2028, to reach <strong>USD 4.53 billion<\/strong>. The demand for neurovascular devices is gaining importance owing to the rising prevalence of the target patient population, increasing demand for minimally invasive neurosurgical procedures, ongoing development of technologically advanced products, and rising R&amp;D investments, among others.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-vivasure-medical-announced-100th-patient-enrolled-in-the-us-pivotal-study-of-its-vivasure-perqseal-closure-device-system\"><span class=\"ez-toc-section\" id=\"Vivasure_Medical_Announced_100th_Patient_Enrolled_in_the_US_Pivotal_Study_of_its_Vivasure_PerQseal%C2%AE_Closure_Device_System\"><\/span><strong>Vivasure Medical Announced 100th Patient Enrolled in the US Pivotal Study of its Vivasure PerQseal\u00ae Closure Device System<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>On <strong>November 14, 2023<\/strong>, <strong>Vivasure Medical\u00ae<\/strong>, a company pioneering novel fully absorbable technology for percutaneous vessel closure, announced that it had enrolled the 100th patient in its <strong>PATCH Clinical Study<\/strong>, which is a multi-center, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal\u00ae Closure Device System. The US Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval earlier this year to advance the PATCH study.<\/p>\n\n\n\n<p>Many life-saving percutaneous cardiovascular procedures, including transcatheter aortic valve replacement (TAVR), thoracic and abdominal endovascular aneurysm repair (TEVAR and EVAR), and the use of a cardiac assist device (CAD), require large hole arterial access from clinicians. Currently, suture- or collagen-based closure devices or surgical repair are the methods used for large-diameter artery closure. Major vascular complications, including vessel distortion at the closure site that may result in thrombus formation, stenosis, or abrupt closure, can arise from either of these conditions.<\/p>\n\n\n\n<p>The first completely absorbable, suture-less synthetic implant for large-bore vascular punctures is called PerQseal. Its low-profile patch is designed to make deployment easier and more controlled than traditional closure techniques. It can be installed from inside the vessel. Thus far, clinical investigations have demonstrated a low rate of complications and high technical success.<\/p>\n\n\n\n<p>Up to 188 patients from the US and Europe will be enrolled in and followed up on as part of the PATCH pivotal study. The company plans to use the findings of the clinical study to support both the international commercial launch of the PerQseal large-hole vessel closure system and an FDA pre-market approval submission.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>\u201cWe\u2019re grateful to the one hundred patients who have been enrolled in this study to date and the brilliant physician investigators working to gather data about our technology,\u201d<\/em><strong><em> <\/em>said Andrew Glass, Chief Executive Officer of Vivasure Medical<\/strong>.<em> <\/em>Andrew added,<em> \u201cThis marks an important milestone for Vivasure as it brings us closer to our goal of demonstrating PerQseal\u2019s potential in supporting successful percutaneous cardiovascular therapies.\u201d<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>According to<strong> DelveInsight\u2019s \u201c<\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/wound-closure-device-market\"><strong>Wound Closure Devices Market<\/strong><\/a><strong>\u201d report,<\/strong> the global wound closure devices market was valued at <strong>USD 11,507.02<\/strong> million in 2022, growing at a CAGR of <strong>5.65%<\/strong> during the forecast period from 2023 to 2028, to reach <strong>USD 15,988.30 million<\/strong> by 2028. The increase in demand for wound closure devices is primarily due to the increasing number of chronic and acute wounds caused due to traumatic injuries such as falls, accidents, and due to chronic disease-associated wounds. Moreover, rising surgical procedures worldwide, recent product approvals, and technological advancements in the wound closure devices product arena are also expected to boost the market for wound closure devices.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>GE HealthCare and Masimo Collaborated on Patient Monitoring Tech On November 8, 2023, GE HealthCare and Masimo announced a joint agreement to integrate patient monitoring technologies.&nbsp; The goal of the partnership is to incorporate Masimo Signal Extraction Technology (SET) pulse oximetry into GE HealthCare&#8217;s wearable, wireless patient monitoring system, Portrait Mobile. Cloud-native technology powers Portrait [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":25664,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[19791,19307,19608,19607,704,17111,21442,21441,2734,21444,20769,2753,17020,17021,16779,16975,19735,19734,420,19790,19789,21445,2731,20643,21447,21446],"industry":[],"therapeutic_areas":[17230,17245,17228],"class_list":["post-25649","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-breast-cancer-diagnostics","tag-breast-cancer-diagnostics-market","tag-bronchoscopes","tag-bronchoscopes-market","tag-fda","tag-ge-healthcare","tag-gyneco-obstetric-ultrasound-systems","tag-gyneco-obstetric-ultrasound-systems-market","tag-johnson-and-johnson","tag-lunit","tag-masimo","tag-medical-device","tag-medical-devices","tag-medical-devices-market","tag-medtech","tag-medtech-market","tag-neurovascular-devices","tag-neurovascular-devices-market","tag-news","tag-patient-monitoring-devices","tag-patient-monitoring-devices-market","tag-route-92-medical","tag-samsung","tag-vivasure-medical","tag-wound-closure-devices","tag-wound-closure-devices-market","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>MedTech News | Samsung, Lunit, Vivasure, Route 92 Medical, GE<\/title>\n<meta name=\"description\" content=\"GE and Masimo&#039;s Collaboration; Samsung&#039;s Ultrasound System \u2018V6\u2019; FDA Nod for Lunit INSIGHT DBT; Vivasure PerQseal Closure Device System Study\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MedTech News | Samsung, Lunit, Vivasure, Route 92 Medical, GE\" \/>\n<meta property=\"og:description\" content=\"GE and Masimo&#039;s Collaboration; Samsung&#039;s Ultrasound System \u2018V6\u2019; FDA Nod for Lunit INSIGHT DBT; Vivasure PerQseal Closure Device System Study\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-16T12:30:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-27T12:35:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/16175900\/16-11-23.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MedTech News | Samsung, Lunit, Vivasure, Route 92 Medical, GE","description":"GE and Masimo's Collaboration; Samsung's Ultrasound System \u2018V6\u2019; FDA Nod for Lunit INSIGHT DBT; Vivasure PerQseal Closure Device System Study","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge","og_locale":"en_US","og_type":"article","og_title":"MedTech News | Samsung, Lunit, Vivasure, Route 92 Medical, GE","og_description":"GE and Masimo's Collaboration; Samsung's Ultrasound System \u2018V6\u2019; FDA Nod for Lunit INSIGHT DBT; Vivasure PerQseal Closure Device System Study","og_url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-11-16T12:30:00+00:00","article_modified_time":"2024-09-27T12:35:12+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/16175900\/16-11-23.webp","type":"image\/webp"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge","url":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge","name":"MedTech News | Samsung, Lunit, Vivasure, Route 92 Medical, GE","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/16175900\/16-11-23.webp","datePublished":"2023-11-16T12:30:00+00:00","dateModified":"2024-09-27T12:35:12+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"GE and Masimo's Collaboration; Samsung's Ultrasound System \u2018V6\u2019; FDA Nod for Lunit INSIGHT DBT; Vivasure PerQseal Closure Device System Study","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/medtech-news-for-samsung-lunit-vivasure-ge#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/16175900\/16-11-23.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/16175900\/16-11-23.webp","width":772,"height":482,"caption":"MedTech News for Samsung, Lunit, Vivasure"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/11\/16175900\/16-11-23-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer Diagnostics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Breast Cancer Diagnostics Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bronchoscopes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bronchoscopes Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GE Healthcare<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gyneco-Obstetric Ultrasound Systems<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gyneco-Obstetric Ultrasound Systems Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Johnson and Johnson<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lunit<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Masimo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">medical device<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Medical Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">MedTech Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurovascular Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurovascular Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Patient Monitoring Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Patient Monitoring Devices Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Route 92 Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">SAMSUNG<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vivasure Medical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Wound Closure Devices<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Wound Closure Devices Market<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Breast Cancer Diagnostics<\/span>","<span class=\"advgb-post-tax-term\">Breast Cancer Diagnostics Market<\/span>","<span class=\"advgb-post-tax-term\">Bronchoscopes<\/span>","<span class=\"advgb-post-tax-term\">Bronchoscopes Market<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">GE Healthcare<\/span>","<span class=\"advgb-post-tax-term\">Gyneco-Obstetric Ultrasound Systems<\/span>","<span class=\"advgb-post-tax-term\">Gyneco-Obstetric Ultrasound Systems Market<\/span>","<span class=\"advgb-post-tax-term\">Johnson and Johnson<\/span>","<span class=\"advgb-post-tax-term\">Lunit<\/span>","<span class=\"advgb-post-tax-term\">Masimo<\/span>","<span class=\"advgb-post-tax-term\">medical device<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices<\/span>","<span class=\"advgb-post-tax-term\">Medical Devices Market<\/span>","<span class=\"advgb-post-tax-term\">MedTech<\/span>","<span class=\"advgb-post-tax-term\">MedTech Market<\/span>","<span class=\"advgb-post-tax-term\">Neurovascular Devices<\/span>","<span class=\"advgb-post-tax-term\">Neurovascular Devices Market<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Patient Monitoring Devices<\/span>","<span class=\"advgb-post-tax-term\">Patient Monitoring Devices Market<\/span>","<span class=\"advgb-post-tax-term\">Route 92 Medical<\/span>","<span class=\"advgb-post-tax-term\">SAMSUNG<\/span>","<span class=\"advgb-post-tax-term\">Vivasure Medical<\/span>","<span class=\"advgb-post-tax-term\">Wound Closure Devices<\/span>","<span class=\"advgb-post-tax-term\">Wound Closure Devices Market<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Nov 16, 2023","modified":"Updated on Sep 27, 2024"},"absolute_dates_time":{"created":"Posted on Nov 16, 2023 6:00 pm","modified":"Updated on Sep 27, 2024 6:05 pm"},"featured_img_caption":"MedTech News for Samsung, Lunit, Vivasure","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25649","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25649"}],"version-history":[{"count":2,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25649\/revisions"}],"predecessor-version":[{"id":29798,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25649\/revisions\/29798"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25664"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25649"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25649"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25649"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25649"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25649"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}